Blue Steens Newsletter

Blue Steens Newsletter

Share this post

Blue Steens Newsletter
Blue Steens Newsletter
Blue Steens in April 2020

Blue Steens in April 2020

Catch up on Blue Steens articles and venture further

Apr 29, 2020
3

Share this post

Blue Steens Newsletter
Blue Steens Newsletter
Blue Steens in April 2020
2
Share

This month on Blue Steens

Federated learning in healthcare

Federated learning is a machine learning paradigm that allows to train algorithms collaboratively without the need for source data exchange between the parties.

Read >>

The winding path from lab to patient

Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those in need.

Read >>


Beyond Blue Steens

Coronavirus

⊳ Testing

For a quick explanation of the difference between genetic (PCR) and antibody (serological) tests, check out last month’s COVID-19 Testing section. Note that a newly-infected person does not yet have antibodies but will have genetic virus material. In contrast, a person who has overcome the infection, may not have detectable genetic material anymore but will have antibodies. Hence, timing of these tests is important.

  • Antibody tests:

    Overall, these tests are still very unreliable and have been criticised, e.g. here and here. However, the FDA tightens its enforcement.

    Meanwhile:

    • Authorisations: Cellex (US), Biolidics (Singapore), DiaSorin (US, Italy)

    • Hangzhou Biotest Biotech/Premier Biotech’s test was used for screening by the University of Southern California and LA Department of Public Health.

  • PCR tests:

    • US saliva tests from Rutgers University, MicroGen DX. Using spit instead of swabs makes sample collection easier.

    • Emergency use authorisation for point-of-care kit that yields positive results in 5 min, negative results in 13 min.

  • Inflatable P2 Lab for Emergency Testing

  • 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Glasgow University to host new Covid-19 testing facility - The uni lab will be staffed by > 500 volunteers and begin work in mid-April. A few companies, Wellcome Trust and University of Dundee also involved.

⊳ Treatment

  • Plasma therapy uses blood plasma from survivors (i.e. the cell-free liquid part of blood containing antibodies) as treatment for patients:

    • Convalescent Plasma to Treat COVID-19: Possibilities and Challenges (academic journal editorial)

    • FDA, EC offer guidance on COVID-19 convalescent plasma

    • Spain's Grifols to test plasma therapy for COVID-19 with U.S. FDA

    • Covid-19: Pakistani doctors get approval for plasma therapy clinical trial

    • Kerala, the first Indian state ready to try Covid-19 plasma therapy has no critically-ill patients for trials

    • Convalescent plasma transfusion shows promise in small Chinese study

  • Remdesivir:

    • Noticed that this one escaped me in March: Gilead requested to lose (!) orphan drug designation due to public backlash.

    • Gilead supersizes trials

    • After struggling previously to supply patients (March review), Gilead has promised to donate 1.5M doses.

  • (Hydroxy-) Chloroquine:

    • FDA authorisations & FDA warning

    • However, a preliminary meta-analysis casts doubts.

    • Trials announced: Novartis (450 patients planned), GNS561 (Phase 2)

    • Meanwhile, production is being ramped up: W Balkan, Novartis (30M of 130M promised doses shipped), Sanofi

    • India lifted export ban

  • Immunosuppressants:

    These drugs aim to prevent a potentially fatal overreaction of the immune system to the infection.

    • InflaRx uses anti-C5a antibodies. [German]

    • Tiziana develops handheld inhaler/nebuliser to be used to deliver anti-IL-6 receptor antibodies directly into patient’s lungs.

  • BioCryst launches early-stage study of galidesivir for COVID-19 - Phase 1 trial of broad-spectrum antiviral in Brazil.

  • Clinical trial with heartburn drug famotidine

  • Collaboration of 15 pharma companies with Gates Foundation includes sharing of proprietary compound libraries.

  • Phase 3 trial with diabetes drug, dapagliflozin, to reduce C-19 disease progression and complications.

  • 🏴󠁧󠁢󠁳󠁣󠁴󠁿 NovaBiotics’s Nylexa to treat potentially lethal secondary bacterial lung infections in C-19 patients. Trials could start in 2nd half of 2020.

⊳ Vaccination

  • Pharma collaborations:

    • BioNTech & Pfizer [German] - Phase-1/2 trial OK in Germany

    • Pfizer collaborating within healthcare ecosystem

    • NIH & 16 drug companies (treatments & vaccines)

    • Sanofi & GSK - Clinical trials expected in 2nd half of 2020.

    • VBI Vaccines & National Research Council of Canada - Aiming to develop a vaccine against various coronaviruses to induce wider immunity.

  • China approves two experimental vaccines to enter clinical trials

  • Novavax fast-tracks phase 1 testing - Start by mid-May.

  • Johnson & Johnson identifies a lead COVID-19 vaccine candidate - Human trials expected by Sep 2020. J&J intend to provide it on a not-for-profit basis.

  • University of Pittsburgh found potential vaccine - Animal results promising. FDA application for clinical trials underway.

⊳ Other news

  • Number and severity of COVID-19 mutations: NextStrain (at least 8 strains), Zhejiang University (at least 30 mutations, medRxiv source)

  • Virological assessment of hospitalized patients with COVID-19 - Analysis of 9 patients with mild symptoms. Some key takeaways: patients highly contagious in 1st week and still potentially contagious after symptoms have gone; antibodies detectable after 7-14 days.

Biotech

  • Scientists have created a new type of robot that is literally alive - The so-called xenobots are part living cells, part machine. They are programmable to take on different forms, self-heal and complete tasks. Their life span is about 1 week. Let’s hope bioethics catch up quickly with the tech evolution.

  • Flagship raises $1.1B to create biotechs for post-pandemic world - Whilst loads of funding is currently pouring into finding solutions for the COVID-19 crisis, Flagship Pioneering is thinking about opportunities in the 3 years after this crisis and is ready to fund a “new generation of companies”. A significant focus area is disease prevention.

Medtech

  • Storing medical information below the skin’s surface - Applying near-infrared dye (quantum dots) alongside vaccine as proof of vaccination.

  • Korean Regulator OKs 1st AI-based cancer diagnosis software (prostate cancer)

Out and about

More like ‘in and about’ these days…

  • CARES, FEMA, COVID19: What healthcare providers, entities need to know (EY), 30 Mar 2020

    Request on-demand recoding here.

  • Blockchain for Medical Research - Book Release, 31 Mar 2020

    Virtual book release. Here’s an article about the book & excerpts from Chapter 15.

  • Stop COVID-19 Hackathon, 13 Apr-11 May 2020

  • EY Global Blockchain Summit, 21-23 Apr 2020

    Twitter avatar for @blue_steens
    Chris @blue_steens
    "Transparency is going to be a licence to operate." Rodrigo Santibanez, panelist at @EYnews global #blockchain summit. #Pharmaceuticals #innovation #pharmaindustry #biotech @pbrody
    5:30 PM ∙ Apr 21, 2020
    Twitter avatar for @blue_steens
    Chris @blue_steens
    Blockchain is not just about improving efficiency & transparency but also about creating new revenue streams for biz. - Chen Zur, panelist at @EYnews global #blockchain summit. #supplychainmanagement #supplychain #foodindustry #trackandtrace #sustainabledevelopment
    6:25 PM ∙ Apr 21, 2020
    Twitter avatar for @blue_steens
    Chris @blue_steens
    "Move fast and break things won't work here. We have to understand the risks." - Robert Bench at @EYnews global #blockchain summit. #FederalReserve #fintech #Governance #riskmanagement
    Image
    7:31 PM ∙ Apr 22, 2020
  • STM and Center for Open Science: US Workshop – April 2020, 27 Apr 2020

  • MediLedger Webinar #2: Contracts & Chargebacks (Chronicled), 28 Apr 2020

    Twitter avatar for @blue_steens
    Chris @blue_steens
    Legacy systems can be hooked up by the sound of it. Design w/ user in mind. "There is a reason biz do biz the way they do." Transition rather than disruption. #innovation #blockchaintechnology #pharmaindustry @ChronicledInc
    Twitter avatar for @blue_steens
    Chris @blue_steens
    Interesting @mediledger Webinar #2 just kicked off. It's about managing #Pharmaceuticals Contracts & Chargebacks thru #blockchain by putting as little (!) info as necessary on-chain. #lifesciences #supplychain #healthcare #procurement #distribution
    5:40 PM ∙ Apr 28, 2020

Connect on Twitter, LinkedIn or YouTube if you like.


In this newsletter I share personal views and observations only. For more information and the privacy policy visit Blue Steens.

3

Share this post

Blue Steens Newsletter
Blue Steens Newsletter
Blue Steens in April 2020
2
Share

Discussion about this post

User's avatar
Chris's avatar
Chris
May 4, 2020

STM recording: https://youtu.be/fJ04m5XXQl0

Expand full comment
Reply
Share
Chris's avatar
Chris
May 1, 2020

Mediledger webinar recording: https://youtu.be/vHar6f5HmnA. Slides: https://uploads-ssl.webflow.com/5e387f889619c7f925b2ed39/5eaa2c7f44c11705e974ac80_MediLedger%20Webinar%20%232_%205%20Ways%20Blockchain%20can%20Resolve%20Chargeback%20Disputes%20Before%20they%20Start.pdf

Expand full comment
Reply
Share

No posts

Ready for more?

© 2025 Christiane Wirrig
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share